pdufa.bio
Home › CRL letters › April 2026

FDA complete response letters, April 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 10, 2026 12:55 AM ET

The FDA's public release of complete response letters holds 5 letters dated April 2026 (openFDA, last updated 2026-08-26). Of the 18 FDA decisions on PDUFA goal dates pdufa.bio tracked in April 2026, 6 were Complete Response Letters.

Released by the FDA, dated April 2026 · 5

Letter dateCompanyApplicationopenFDA statusLetter
2026-04-23Grace Therapeutics U.S., Inc.NDA 220304Unapprovedletter (PDF)
2026-04-22AbbVie Inc.BLA 761459Unapprovedletter (PDF)
2026-04-13Eagle Pharmaceuticals, Inc.NDA 220045Unapprovedletter (PDF)
2026-04-10Replimune, Inc.BL 125827Unapprovedletter (PDF)
2026-04-10Telix Pharmaceuticals (US) Inc.BLA 761401Unapprovedletter (PDF)

Complete Response Letters among decisions pdufa.bio tracked · 6

FDA actionTickerDrugSource
2026-04-23GRCEGTX-104 - (STRIVE-ON)decision page
2026-04-23ABBVtrenibotulinumtoxinE (Trenibotdecision page
2026-04-10REPLRP1 (vusolimogene oderparepvecdecision page
2026-04-08MGNXZYNYZ (retifanlimab-dlwr) - (Pdecision page
2026-04-08INCYZYNYZ (retifanlimab-dlwr) - (Pdecision page
2026-04-07OTLKLYTENAVA (bevacizumab-vikg) /decision page
A Complete Response Letter is the FDA's notice that it will not approve an application in its current form; it is not a permanent rejection, and the sponsor can resubmit. The two counts come from different records and are not added together. ← March 2026 · May 2026 → · all released letters · every CRL decision we tracked